WHY WAS THIS FUNDED?

HHS has authority to enter contracts with private companies to advance public health goals, including developing medical countermeasures against diseases and biological threats. The specific legal authority or program behind this award is not clearly identified in the available data.

WHAT PUBLIC PROBLEM IS IT TRYING TO SOLVE?

Regeneron is a pharmaceutical company known for developing antibody-based treatments, so this contract likely relates to creating or supplying medicines that protect the public from disease outbreaks or other health emergencies. However, the exact public health problem this contract is meant to solve is not specified in the available data.

WHO BENEFITS?

Potential beneficiaries include Americans who may need access to treatments developed or supplied under this contract, as well as Regeneron employees and researchers whose work is supported by this funding. The broader U.S. public health and emergency preparedness system may also benefit.

WHAT ARE THE RISKS?

A contract of this size and length, running 14 years, carries risks related to oversight, since it can be difficult to ensure taxpayer money is used efficiently over such a long period. There is also a risk that the medical products developed may not perform as expected or may not end up being needed at the scale originally anticipated.

WHAT HAPPENS IF FUNDING IS REMOVED?

If this contract were cancelled, any medical treatments or countermeasures being developed or stockpiled under the agreement could be delayed or lost, potentially leaving gaps in the country's public health preparedness. Regeneron could also face significant financial and operational disruption tied to the work it has planned around this contract.

ARGUMENTS FOR

• •Long-term government investment in pharmaceutical partnerships can help ensure the U.S. has access to critical medicines during emergencies, without waiting for a crisis to begin.
• •Partnering with an established company like Regeneron, which has a track record in antibody treatments, may reduce the time and risk involved in developing new medical countermeasures.
• •A 14-year contract provides stability that encourages sustained research and development, which shorter contracts may not allow.

ARGUMENTS AGAINST

• •Nearly $974 million committed over 14 years is a very large sum, and without clear public details on deliverables, it is difficult for taxpayers to judge whether they are getting good value.
• •Long-term, single-company contracts can reduce competition, which typically helps control costs and improve quality in government procurement.
• •If the medical needs or health threats the contract was designed to address change significantly over time, the government may still be locked into payments that no longer match current priorities.